LIVIVO - Search results -

Search results

Result 1 - 10 of total 75

Search options

Book: Managing cardiovascular complications in diabetes

Betteridge, D. John / Nicholls, Stephen J.

2014

Author's details	ed. by D. John Betteridge ; Stephen Nicholls
Keywords	Diabetes/Complications ; Cardiovascular system/Diseases
Subject code	616.462
Language	English
Size	XIII, 319 S., [2] Bl. : Ill., graph. Darst., 25 cm
Publisher	Wiley Blackwell
Publishing place	Chichester
Publishing country	Great Britain
Document type	Book
Note	Includes bibliographical references and index ; The vascular endothelium in diabetes / Andrew Lansdown, Elizabeth Ellins, and Julian Halcox -- New biomarkers of cardiovascular disease in diabetes / Hitesh Patel, Sujay Chandran, and Kausik K. Ray -- Kidney disease in diabetes / Amanda Y. Wang, Meg Jardine, and Vlado Perkovic -- Vascular imaging / Kiyoko Uno, Jordan Andrews, and Stephen J. Nicholls -- Glycemia and CVD and its management / Jeffrey W. Stephens, Akhila Mallipedhi, and Stephen C. Bain -- Hypertension and cardiovascular disease and its management / José A. García-Donaire and Luis M. Ruilope -- Dyslipidemia and its management in type 2 diabetes / D. John Betteridge -- Thrombosis in diabetes and its clinical management / R.A. Ajjan and Peter J. Grant -- Diet and lifestyle in CVD prevention and treatment / Alice H. Lichtenstein -- Management of acute coronary syndrome / Christopher M. Huff and A. Michael Lincoff -- Management of peripheral arterial disease / Rüdiger-Egbert Schernthaner, Gerit-Holger Schernthaner, and Guntram Schernthaner
HBZ-ID	HT018299819
ISBN	978-0-470-65949-6 ; 0-470-65949-1
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2014 A 2451	available for loan (reading room)	Lesesaal EG

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Conference proceedings: Targeting dyslipidemia - the key to CHD risk reduction in the diabetic population

Betteridge, D. John

proceedings from a symposium held 5th September 2004 at the 40th annual meeting of the European Association for the Study of Diabetes [Munich]

(Diabetes research and clinical practice ; 68, Suppl. 2)

2005

Institution	European Association for the Study of Diabetes
Author's details	guest ed. D. John Betteridge
Series title	Diabetes research and clinical practice ; 68, Suppl. 2
Collection
Language	English
Size	S42 S. : graph. Darst.
Publisher	Elsevier
Publishing place	Amsterdam u.a.
Publishing country	Netherlands
Document type	Book ; Conference proceedings
HBZ-ID	HT014431893
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 2047 -68,Suppl.2-	not available for loan	Zeitschriften-Lesesaal

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Diabetogenic Action of Statins: Mechanisms.

Carmena, Rafael / Betteridge, D John

Current atherosclerosis reports

2019 Volume 21, Issue 6, Page(s) 23

Abstract: Purpose of review: Observational studies and meta-analyses of randomized clinical trials data have revealed a 10-12% increased risk of new-onset diabetes (NOD) associated with statin therapy; the risk is increased with intensive treatment regimens and ... ...

Abstract	Purpose of review: Observational studies and meta-analyses of randomized clinical trials data have revealed a 10-12% increased risk of new-onset diabetes (NOD) associated with statin therapy; the risk is increased with intensive treatment regimens and in people with features of the metabolic syndrome or prediabetes. The purpose of this review is to provide an updated summary of what is known about the potential mechanisms for the diabetogenic effect of statins. Recent findings: Hydroxyl methyl glutaryl coenzyme A reductase (HMGCoAR) is the target of statin therapy and the activity of this key enzyme in cholesterol synthesis is reduced by statins in a partial and reversible way. Mendelian randomization studies suggest that the effect of statins on glucose homeostasis reflect reduced activity of HMGCoAR. In vitro and in vivo data indicate that statins reduce synthesis of mevalonate pathway products and increase cholesterol loading, leading to impaired β-cell function and decreased insulin sensitivity and insulin release. While this effect has been thought to be a drug class effect, recent insights suggest that pravastatin and pitavastatin could exhibit neutral effects on glycaemic parameters in patients with and without diabetes mellitus. The mechanisms by which statins might lead to the development of NOD are unclear. The inhibition of HMGCoAR activity by statins appears to be a key mechanism. It is difficult to offer a comprehensive view regarding the diabetogenic effect of statins because our understanding of the most widely recognized potential mechanisms, i.e. underlying statin-induced reduction of insulin sensitivity and/or insulin secretion, is still far from complete. The existence of this dual mechanism is supported by the results of a study in a large group of non-diabetic men, showing that a 46% higher risk of NOD in statin users compared to non-users was accompanied by a significant 12% reduction in insulin secretion and a 24.3% increase in insulin resistance. Although statin therapy is associated with a modest increase in the risk of NOD (about one per thousand patient-years), patients should be reassured that the benefits of statins in preventing cardiovascular disease (CVD) events far outweigh the potential risk from elevation in plasma glucose.
MeSH term(s)	Aged ; Animals ; Blood Glucose/drug effects ; Cardiovascular Diseases/prevention & control ; Cholesterol/metabolism ; Diabetes Mellitus, Type 2/chemically induced ; Diabetes Mellitus, Type 2/epidemiology ; Humans ; Hydroxymethylglutaryl CoA Reductases/metabolism ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Incidence ; Insulin/metabolism ; Male ; Metabolic Syndrome/chemically induced ; Mice ; Middle Aged ; Pravastatin/therapeutic use ; Quinolines/therapeutic use ; Risk Factors
Chemical Substances	Blood Glucose ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Insulin ; Quinolines ; Cholesterol (97C5T2UQ7J) ; Hydroxymethylglutaryl CoA Reductases (EC 1.1.1.-) ; Pravastatin (KXO2KT9N0G) ; pitavastatin (M5681Q5F9P)
Language	English
Publishing date	2019-04-30
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057369-8
ISSN	1534-6242 ; 1523-3804
ISSN (online)	1534-6242
ISSN	1523-3804
DOI	10.1007/s11883-019-0780-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5534: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.

Betteridge, D John

Nature reviews. Endocrinology

2013 Volume 9, Issue 2, Page(s) 76–78

Abstract: Systemic administration of anti-PCSK9 antibodies induces dramatic reductions in LDL-cholesterol levels, and the effect of this therapy on LDL-receptor activity seems to be additive to that of statin therapy. Inhibition of PCSK9 is potentially very ... ...

Abstract	Systemic administration of anti-PCSK9 antibodies induces dramatic reductions in LDL-cholesterol levels, and the effect of this therapy on LDL-receptor activity seems to be additive to that of statin therapy. Inhibition of PCSK9 is potentially very important to the clinician, and should enable more patients to achieve their LDL-cholesterol-level goal.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Anticholesteremic Agents/administration & dosage ; Anticholesteremic Agents/therapeutic use ; Cholesterol, LDL/metabolism ; Clinical Trials as Topic ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/drug therapy ; Proprotein Convertase 9 ; Proprotein Convertases/antagonists & inhibitors ; Serine Endopeptidases
Chemical Substances	Antibodies, Monoclonal ; Anticholesteremic Agents ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; Proprotein Convertases (EC 3.4.21.-) ; Serine Endopeptidases (EC 3.4.21.-)
Language	English
Publishing date	2013-01-08
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2489381-X
ISSN	1759-5037 ; 1759-5029
ISSN (online)	1759-5037
ISSN	1759-5029
DOI	10.1038/nrendo.2012.254
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6336: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 93: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Lipid control in patients with diabetes mellitus.

Betteridge, D John

Nature reviews. Cardiology

2011 Volume 8, Issue 5, Page(s) 278–290

Abstract: Patients with diabetes mellitus are at increased risk of cardiovascular disease (CVD). Dyslipidemia, an important component of the insulin resistance syndrome and type 2 diabetes, is strongly related to CVD risk and is open to therapeutic intervention. ... ...

Abstract	Patients with diabetes mellitus are at increased risk of cardiovascular disease (CVD). Dyslipidemia, an important component of the insulin resistance syndrome and type 2 diabetes, is strongly related to CVD risk and is open to therapeutic intervention. Statins have proved to be safe, very-well tolerated, and highly effective in reducing the levels of LDL cholesterol and apolipoprotein B. Primary and secondary CVD prevention trials have shown that use of statins leads to highly significant reductions in the incidence of major CVD events. A wealth of data on the outcomes of statin therapy is now available to guide clinical practice in the population of patients with type 2 diabetes. Statin therapy in patients with type 1 diabetes seems to have a similar benefit to that seen in patients with type 2 diabetes. However, despite statin therapy, high CVD risk persists in these populations. More-intensive statin therapy produces greater reduction in the incidence of CVD events, but a more-global approach to lipid management is likely to result in further risk reduction. After reductions in the levels of LDL cholesterol and apolipoprotein B, the next target of lipid-lowering therapy is to increase HDL-cholesterol levels, which tend to be low in patients with type 2 diabetes. The most effective HDL-cholesterol-raising agent currently available for use in clinical practice is niacin. Trials with surrogate end points have pointed to the cardiovascular benefit of adding niacin to statin therapy. Large CVD end point trials, which include many patients with diabetes, are underway to test the combination of a statin and niacin versus a statin alone.
MeSH term(s)	Biomarkers/blood ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 2/complications ; Dyslipidemias/blood ; Dyslipidemias/complications ; Dyslipidemias/drug therapy ; Evidence-Based Medicine ; Humans ; Hypolipidemic Agents/therapeutic use ; Lipids/blood ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Treatment Outcome
Chemical Substances	Biomarkers ; Hypolipidemic Agents ; Lipids
Language	English
Publishing date	2011-03-15
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2490375-9
ISSN	1759-5010 ; 1759-5002
ISSN (online)	1759-5010
ISSN	1759-5002
DOI	10.1038/nrcardio.2011.23
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6019: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 98: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The diabetogenic action of statins - mechanisms and clinical implications.

Betteridge, D John / Carmena, Rafael

Nature reviews. Endocrinology

2016 Volume 12, Issue 2, Page(s) 99–110

Abstract: Treatment with statins has transformed primary and secondary prevention of cardiovascular disease (CVD), including thrombotic stroke. Evidence-based data demonstrate the benefits and safety of statin therapy and help to guide clinicians in the management ...

Abstract	Treatment with statins has transformed primary and secondary prevention of cardiovascular disease (CVD), including thrombotic stroke. Evidence-based data demonstrate the benefits and safety of statin therapy and help to guide clinicians in the management of populations at high risk of CVD. Nevertheless, clinical trials, meta-analyses and observational studies highlight a 10-12% increase in new-onset diabetes mellitus (NODM) among patients receiving statins. The risk further increases with intensive therapy and among individuals with known risk factors for NODM. Mechanisms underpinning this effect are not yet fully understood; however, Mendelian randomization studies suggest that they are related to lowered activity of HMG-CoA reductase, the target of statin therapy. In vitro research indicates that statins potentially impair β-cell function and decrease insulin sensitivity but how these findings relate to patients is unknown. In the clinic, statins should be prescribed on the basis of CVD risk and individual patient characteristics. In addition, diet and lifestyle interventions should be emphasized to help mitigate the risk of NODM. Individuals who develop NODM while taking statins do not exhibit increased microvascular disease, which is reassuring. In diabetes mellitus of long duration, the effect of statins on glycaemic control is small and unlikely to be clinically important.
MeSH term(s)	Animals ; Cardiovascular Diseases/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Diabetes Mellitus, Type 2/genetics ; Diabetes Mellitus, Type 2/prevention & control ; Feeding Behavior ; Humans ; Hydroxymethylglutaryl CoA Reductases/genetics ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; In Vitro Techniques ; Insulin Resistance ; Insulin-Secreting Cells/drug effects ; Mendelian Randomization Analysis ; Risk Factors ; Risk Reduction Behavior ; Secondary Prevention
Chemical Substances	Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hydroxymethylglutaryl CoA Reductases (EC 1.1.1.-)
Language	English
Publishing date	2016-02
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2489381-X
ISSN	1759-5037 ; 1759-5029
ISSN (online)	1759-5037
ISSN	1759-5029
DOI	10.1038/nrendo.2015.194
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6336: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 93: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book: Clinicians' guide to lipids and coronary heart disease

Betteridge, Denis John / Morrell, Jonathan M.

2003

Author's details	D. J. Betteridge and J. M. Morrell
Keywords	Lipids / metabolism ; Lipoproteins / metabolism ; Coronary Disease / etiology ; Coronary Disease / prevention & control ; Coronary Disease / therapy
Language	English
Size	XVI, 368 S. : Ill., graph. Darst.
Edition	2. ed.
Publisher	Arnold
Publishing place	London u.a.
Publishing country	Great Britain
Document type	Book
HBZ-ID	HT013627059
ISBN	0-340-76408-2 ; 978-0-340-76408-4
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2003 A 1162	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Conference proceedings: CHD and diabetes - target dyslipidaemia, reduce the risk

Betteridge, Denis John

proceedings of the satellite symposium to the 38th congress of the European Association for the Study of Diabetes, September 1 (2002), Budapest, Hungary

(Diabetes research and clinical practice ; 61, Suppl. 1)

2003

Institution	European Association for the Study of Diabetes
Author's details	guest ed. D. John Betteridge
Series title	Diabetes research and clinical practice ; 61, Suppl. 1
Collection
Language	English
Size	S39 S. : graph. Darst.
Publisher	Elsevier
Publishing place	Amsterdam u.a.
Publishing country	Netherlands
Document type	Book ; Conference proceedings
HBZ-ID	HT013849963
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 2047 -61,Suppl.1-	not available for loan	Zeitschriften-Lesesaal

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.

Betteridge, D John

Fundamental & clinical pharmacology

2009 Volume 23, Issue 6, Page(s) 675–679

Abstract: Recent trials of intensive glycaemic control in patients with type 2 diabetes and its impact on cardiovascular disease have led to confusion and speculation amongst physicians. The Action to Control Cardiovascular Risk in Diabetes Study was terminated ... ...

Abstract	Recent trials of intensive glycaemic control in patients with type 2 diabetes and its impact on cardiovascular disease have led to confusion and speculation amongst physicians. The Action to Control Cardiovascular Risk in Diabetes Study was terminated early because of a significant excess all-cause mortality in the intensively-treated group. Furthermore the ADVANCE and VADT trials did not demonstrate cardiovascular benefit with more intensive glycaemic control. Against this background, it is pertinent to re-visit and critically appraise the results of the PROactive study which examined the effects of the thiazolidinedione, pioglitazone, on cardiovascular end-points in a large, randomized, placebo-controlled clinical trial in type 2 diabetic patients with symptomatic disease. PROactive has been rightly criticized in the choice of its composite primary end-point which included a physician-driven as opposed to a disease-driven outcome, namely peripheral vascular re-vascularization. This was primarily responsible for the primary composite end-point not being achieved; whereas there was a significant beneficial impact on the major secondary end-point of death, non-fatal myocardial infarction and stroke. The results of PROactive have been supported by two subsequent studies examining the impact of pioglitazone on important surrogates of atherosclerosis, namely carotid intima/medial thickness (IMT) and coronary atheroma volume as delineated with intravascular ultrasound. The CHICAGO study demonstrated that IMT in type 2 diabetic patients treated with pioglitazone did not progress whereas those treated with glimepiride showed progression. In PERISCOPE atheroma volume progressed with glimepiride but did not with pioglitazone. This is exciting data pointing to the cardiovascular benefits of pioglitazone. In PROactive, CHICAGO and PERISCOPE there was a sustained effect of pioglitazone on glycaemic control and, in addition, beneficial effects in reducing triglycerides and increasing HDL-cholesterol beyond that seen with concomitant statin therapy. These findings strongly suggest that pioglitazone has an important place in the management of type 2 diabetes.
MeSH term(s)	Cardiovascular Diseases/etiology ; Cardiovascular Diseases/physiopathology ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Randomized Controlled Trials as Topic ; Risk Assessment ; Thiazolidinediones/adverse effects ; Thiazolidinediones/therapeutic use
Chemical Substances	Hypoglycemic Agents ; Thiazolidinediones ; pioglitazone (X4OV71U42S)
Language	English
Publishing date	2009-12
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	639134-5
ISSN	1472-8206 ; 0767-3981
ISSN (online)	1472-8206
ISSN	0767-3981
DOI	10.1111/j.1472-8206.2009.00741.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2247: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Conference proceedings: Dyslipidaemia in the diabetic patient

Betteridge, Denis John

proceedings of a satellite symposium held during the 35th meeting of the European Association for the Study of Diabetes, 29th September 1999, Brussels

(Acta diabetologica ; 38, Suppl. 1)

2001

Institution	European Association for the Study of Diabetes
Author's details	guest ed. D. John Betteridge
Series title	Acta diabetologica ; 38, Suppl. 1
Collection
Language	English
Size	A4, S26 S. : graph. Darst.
Publisher	Springer
Publishing place	Milano
Publishing country	Italy
Document type	Book ; Conference proceedings
HBZ-ID	HT013252767
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 611 -38,Suppl.1-	not available for loan	Zeitschriften-Lesesaal

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito